中国麻风皮肤病杂志 ›› 2025, Vol. 41 ›› Issue (3): 180-183.doi: 10.12144/zgmfskin202503180

• 论著 • 上一篇    下一篇

阿普米司特治疗家族性良性慢性天疱疮二例并文献复习

刘雯慧1,2,陈声利1,2,施仲香1,2,刘红1,2   

  1. 1山东第一医科大学附属皮肤病医院,山东济南,250022;2 山东省皮肤病性病防治研究所,山东济南,250022
  • 出版日期:2025-03-15 发布日期:2025-03-03

Hailey-Hailey disease successfully treated with apremilast: two cases report and literature review

LIU Wenhui1,2, CHEN Shengli1,2, SHI Zhongxiang1,2, LIU Hong1,2   

  1. 1 Hospital for Skin Diseases, Shandong First Medical University, Jinan 250022, China; 2 Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan 250022, China
  • Online:2025-03-15 Published:2025-03-03

PDF (PC)

34

摘要： 家族性良性慢性天疱疮是一种家族性遗传病,目前尚无统一的治疗方案。阿普米司特是一种口服小分子磷酸二酯酶4(PDE 4)抑制剂,国外有报道显示阿普米司特可显著改善家族性良性慢性天疱疮,国内暂无相关报道。本文国内首次报道二例对阿普米司特反应良好的家族性良性慢性天疱疮患者。

关键词: 阿普米司特, 阿维A, 家族性良性慢性天疱疮, PDE4

Abstract: Hailey-Hailey disease is a inheritary disease and there is currently no unified treatment standard. Apremilast, an oral small molecule phosphodiesterase 4 (PDE 4) inhibitor, can significantly improve Hailey-Hailey disease according to foreign reports, but there are no relevant reports in China. This paper reported two patients with Hailey-Hailey disease who had a good response to apremilast in China reported for the first time, and relevant literature was reviewed.

Key words: apremilast, acitretin, Hailey-Hailey disease (HHD), PDE4